A group of NETRF-funded researchers has discovered molecular information that may help predict recurrence of non-functional pancreatic neuroendocrine tumors (pNETs), which do not release excess hormones into the bloodstream. In a paper published today in Nature Medicine, the researchers describe new subtypes of pNETs with vastly different risks of recurrence.
Lead investigator Ramesh Shivdasani, MD, PhD, Dana-Farber Cancer Institute, Harvard Medical School, said the finding moves us closer to being able to identify patients with a high risk for metastasis at diagnosis and initial treatment. “These patients can be monitored vigilantly for recurrent cancers, which may be treatable if detected early, while patients with the less aggressive kind of pNET can be advised that the prognosis is excellent.”
Read the full article on Nature Medicine